LGM
JANX icon

Logos Global Management’s Janux Therapeutics JANX Stock Holding History

Logos Global Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-500,000
Closed -$12.2M – 77
2025
Q3 		$12.2M Hold
500,000
– – 1.1% 35
2025
Q2 		$11.6M Buy
+500,000
New +$13.2M 1.28% 26

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Logos Global Management's JANX Position: Q2 2026 in Review

Logos Global Management sold out of Janux Therapeutics (JANX) in Q2 2026, closing a stake of 1,000,000 shares — an estimated $13.9M sold.

Logos Global Management first reported a position in JANX in Q2 2021 and held it in 12 quarters. The position peaked at $66.9M in Q4 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Logos Global Management reported no remaining Janux Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Logos Global Management sold 1,000,000 Janux Therapeutics shares in Q2 2026, an estimated $13.9M.
  • Logos Global Management first reported a position in Janux Therapeutics in Q2 2021 and held it in 12 quarters.
  • Logos Global Management's Janux Therapeutics position peaked at $66.9M in Q4 2024.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.